Further studies revealed that nRCT significantly enhances the proportion of rectal cancer-infiltrating CD8+ T cells expressing the cytotoxic effector molecule granzyme B. These findings indicate that nRCT significantly alters the frequency and phenotype of pDCs and CD8+ T cells, which may influence the clinical response of rectal cancer patients to nRCT. This evidence concerns the gene CD8A and rectal cancer.